Innovent Biologics, sintilimab, TYVYT, GC101, nolgileucel, advanced melanoma, metastatic melanoma, MIZAR-003, NMPA, tumor-infiltrating lymphocyte therapy, TIL therapy, PD-1 inhibitor, immunotherapy

Suzhou, China, October 26, 2026 Innovent Biologics announced that China’s National Medical Products Administration (NMPA) has accepted for review...